Skip to content

Strategies for improving blood pressure control in Africa

Physiologically individualized therapy for resistant hypertension in Africa

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN69440037
Enrollment
120
Registered
2016-05-31
Start date
2014-07-03
Completion date
Unknown
Last updated
2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resistant hypertension Circulatory System Resistant hypertension

Interventions

On the first study visit, participants have blood samples taken for measurement of plasma renin and aldosterone using kits provided by Diagnostics Biochem Canada Inc, and a sample of blood to be sent
28(3):254-7. PMID: 22289470). Participants in both groups are followed up for one year in the hypertension clinic, with visits scheduled according to the usual routine in each clinic.

Sponsors

Grand Challenges Canada
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Blood pressure greater than 160 systolic or 90 diastolic 2.Currently on three medications including a diuretic 3. Attending the hypertension clinic at the study site 4. Aged 18 and over

Exclusion criteria

Exclusion criteria: 1. Renal failure 2. Congestive heart failure 3. Patients with a serious health condition that would limit life expectancy to less than one year

Design outcomes

Primary

MeasureTime frame
Blood pressure control, defined as a systolic pressure <140 mmHg and Diastolic Control is defined as a diastolic pressure <90, is measured using an automated blood pressure device at baseline and one year.

Secondary

MeasureTime frame
Nucleotide polymorphisms (SNPs) found in the candidate genes are measured using sanger sequencing at baseline in the intervention group only.

Countries

Kenya, Nigeria, South Africa

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 27, 2026